Slide 1: Driving Innovation in Retinal Disease: Clinical Updates
——— ~ ocugen. > ee COURAGEOUS INNOVATION Dedicated to Bringing Game-Changing Gene & Cell Therapies and Vaccines to Market and Working Even Harder to Provide Access to Patients Globally Driving Innovation in Retinal Disease: Clinical Updates for Stargardt, Geographic Atrophy, Retinitis Pigmentosa, an
Slide 2: Forward-Looking Statements
MM Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including, but not limited to, strategy, business plans and objectives for Ocugen’s clinical programs, plans and timelines for the preclinic
Slide 3: We're Here to Make an Impact Through Courageous Innovation
MMM We're Here to Make an Impact Through Courageous Innovation Company Overview Founded 2013 HQ & Manufacturing Malvern, PA Employees ~100 Ticker Symbol OCGN India Business Center Hyderabad Our Values Respect ey Integrity elev. oa Teamwork Accountability — ocugen. —
Slide 4: Leader in Ophthalmology Gene Therapies
_ Leader in Ophthalmology Gene Therapies THREE YEARS. THREE BLAs. Potential for three biologics license applications (BLAs) in the next three years = OCU400 OCU410ST OCU410 BLA BLA BLA — ocugen —
Slide 5: OCU410/OCU410ST (ROFA) for Geographic Atrophy and Stargardt Diseases
OCU410/OCU410ST (ROFA) for the Treatment for Geographic Atrophy and Stargardt Diseases ocugen. — 5
Slide 6: hRORA for Stargardt Disease and Geographic Atrophy Secondary to Dry AMD
Db hRORA for Stargardt Disease (OCU410ST) Geographic Atrophy (GA) Secondary to Dry AMD Prevalence of STGD * ~100,000 patients in the U.S. and Europe * Caused by mutations in ABCA4 * Symptoms appear in childhood and worsen over time No Treatment Options Prevalence of GA Lipid deposits/ Drusen * Advan
Slide 7: OCU410ST (RORA) for the Treatment for Stargardt Disease (GARDian)
OCU410ST (RORA) for the Treatment for Stargardt Disease (GARDian) ocugen NCTOS956626 — 7
Slide 8: Mean Change in BCVA
• • • • • • z 0.8 0.6 0.4 0.2 0.0 Mean Change in BCVA
Slide 9: OCU410 (RORA) for Geographic Atrophy secondary to Dry AMD (ArMaDa)
OCU410 (RORA) for the Treatment for Geographic Atrophy secondary to Dry AMD (ArMaDa) ocugen NCTO6018558 = 9
Slide 10: Phase 1 Safety and Efficacy Summary
MMM Phase 1 Safety and Efficacy Summary Mean Change in LLVA Mean Change f seline 10 a2 o 25 Se «6 £ --- Natural History Studies 30 BS 29-1] + Untreated Eye a A 0 Stabilization a E - -® Treated Eye i= = =a Bes. Se 5 és 29 Decrease o3 aw s= -10 from = é . On Baseline Se cow -15 = = 05 $e -e Treated Ey
Slide 11: OCU410 Treatment Preserves Retinal Tissue in GA Lesions
ane ne on eam ea Single sub-retinal injection of OCU410 at 12M is more effective when compared to PM and PEOM treatment MM 0CU410 Treatment Preserves Retinal Tissue in GA Lesions Phase 2 enrollment complete with 51 subjects (N=17, Med dose; N=17, High dose and N=17 control) 03 0.2 O41 ° Primary: Cha
Slide 12: OCU400 for the treatment of Broad Retinitis Pigmentosa
OCU400® for the treatment of Broad Retinitis Pigmentosa NCT05203939: Phase 1/2 Trial — cugen NCT06388200 : Phase 3 (liMeliGhT) Trial = —
Slide 13: Visual Field Proportion of Responders
• • • • • • Visual Field 0 10 20 30 40 50 60 70 80 P ro p o rt io n o f R e sp o n d e rs 6/8
Slide 14: Phase 3 (liMeliGhT) Trial Design
MMM Phase 3 (liMeliGhT) Trial Design First Phase 3 gene therapy clinical trial to receive broad RP indication from FDA Clinical Assessment Extension study Treatment | It | (2.5110 ve/eye) > RP Patients (n=150) Clinical Assessment Population + Patients 25 years of age with clinical and molecular Prim
Slide 15: OCU200 Phase 1 Study for Diabetic Macular Edema
OCU200 A Phase | Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME) ocugen NCT05802329 15 —
Slide 16: OCU200: Phase 1 Clinical Trial Targeting Diabetic Macular Edema (DME)
| OCU200: Phase 1 Clinical Trial Targeting Diabetic Macular Edema (DME) OCU200 is our novel biologics candidate for sight-threatening conditions + Arecombinant fusion protein of transferrin and tumstatin * Potential to address diabetic macular edema (DME), diabetic retinopathy (DR), wet AMD | High p
Slide 17: Ocugen Vision
MM Ocugen™ Vision Fully integrated, patient-centric biotech company focused on vaccines in support of public health and gene and cell therapies targeting unmet medical needs through Courageous Innovation — ocugen. — 7